Related Experiment Video
Updated: May 30, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
Bupropion-SR for smoking cessation in early recovery from alcohol dependence: a placebo-controlled, double-blind
Maher Karam-Hage1, Stephen Strobbe, Jason D Robinson
1Department of Behavioral Science, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. maherkaram@mdanderson.org
Abstract:
We conducted a double-blind pilot study involving 11 alcohol- and nicotine-dependent patients randomized to receive either bupropion or placebo. Four of six patients on bupropion and one of five patients on placebo were abstinent from smoking at the end of medication phase. Those in the bupropion group reported significantly less craving (p < .02) and less exposure to cigarette smoke over time (expired carbon monoxide; p < .01). There were no serious adverse events and no main effects of medication group on either per subject or total number of adverse events. All those who completed treatment remained abstinent from alcohol.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
CNS Depressants: Alcohol and Nicotine
Blind Procedures
Drug Dependence
